What do you think selling Bydureon will be like?



















Once-a-week compliance will be your one and only selling point... From what I understand Bydureon didn't even meet the non-inferiority endpoint vs. Victoza. And believe me, docs are REALLY liking Victoza right now. Plus, the once-a-week advantage isn't going to last long... Other companies have their own versions in Phase III trials right now.

Also from my experience, inVentiv is terrible with paying out IC. Therefore, this sales force will lose motivation pretty early on. There will be A LOT of stress and pressure with this one, yet no true rewards... other than to keep your job for a few more months or however long the contract is.

Good luck!